Law firm Stephenson Harwood LLP has advised Oxford Biomedica plc (Oxford Biomedica), a gene and cell therapy company, on a Licence and Clinical Supply Agreement (LSA) with Juno Therapeutics, a Bristol Myers Squibb company.

The LSA gives Juno Therapeutics a non-exclusive licence to Oxford Biomedica’s LentiVector platform for CAR-T and TCR-T therapeutics, and puts in place a five year Clinical Supply Agreement.

Under the terms of the LSA, Oxford Biomedica will receive an upfront payment of US$10 million in cash, and up to US$86 million if certain development and regulatory milestones – related to multiple products and indications – are reached. Oxford Biomedica is also entitled to receive up to US$131 million in sales-based milestone payments, and an undisclosed royalty on the net sales of products sold by Juno Therapeutics using the LentiVector platform.

The Stephenson Harwood team was led by partner Dan Holland, with support from associate Katie Samadi. Partner Alexandra Pygall advised on the IP and licensing aspects, while partner Maryanna Sharrock and associate Katie Raine advised on the tax elements.